Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells.

Saved in:
Bibliographic Details
Title: Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells.
Authors: Sahu SU; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA., Castro M; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA., Muldoon JJ; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Asija K; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA., Wyman SK; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA., Krishnappa N; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA., de Oñate L; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA., Eyquem J; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.; Parker Institute for Cancer Immunotherapy, University of California San Francisco, San Francisco, CA, USA.; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.; UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Institute for Human Genetics, University of California San Francisco, San Francisco, CA, USA., Nguyen DN; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA.; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Wilson RC; Innovative Genomics Institute, University of California Berkeley, Berkeley, CA, USA. rosswilson@berkeley.edu.; Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA, USA. rosswilson@berkeley.edu.; California Institute for Quantitative Biosciences at University of California Berkeley, Berkeley, CA, USA. rosswilson@berkeley.edu.
Source: Nature protocols [Nat Protoc] 2025 Oct; Vol. 20 (10), pp. 2735-2770. Date of Electronic Publication: 2025 Mar 03.
Publication Type: Journal Article; Review
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101284307 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-2799 (Electronic) Linking ISSN: 17502799 NLM ISO Abbreviation: Nat Protoc Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1750-2799
DOI:10.1038/s41596-025-01154-8